hereditary thrombophilia

Genetic Markers of Hereditary Thrombophilia and Risk of Thrombotic Complications in Patients with Polycythemia Vera

MYELOID TUMORS , ,

DI Shikhbabaeva, LB Polushkina, VA Shuvaev, IS Martynkevich, SI Kapustin, TB Zamotina, MS Fominykh, VU Udal’eva, II Zotova, VM Shmeleva, OA Smirnova, SV Voloshin, SS Bessmel’tsev, AV Chechetkin, KM Abdulkadyrov

Russian Scientific Research Institute of Hematology and Transfusiology under the Federal Medico-Biological Agency, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024

For correspondence: Dzhariyat Ismailovna Shikhbabaeva, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024; Tel: +7(931)201-71-28; e-mail: djeri.shih@mail.ru

For citation: Shikhbabaeva DI, Polushkina LB, Shuvaev VA, et al. Genetic Markers of Hereditary Thrombophilia and Risk of Thrombotic Complications in Patients with Polycythemia Vera. Clinical oncohematology. 2017;10(1):85–92 (In Russ).

DOI: 10.21320/2500-2139-2017-10-1-85-92

ABSTRACT

Background. Thrombotic complications are one of the main problems of polycythemia vera (PV) treatment. They significantly impair the quality of life of these patients and may lead to the lethal outcome. A thrombotic event often precedes the diagnosis of this hematological disease. The pathogenesis of thrombosis in myeloproliferative neoplasms, PV, in particular, is a complex one. Prescription of antiaggregants in the absence of thrombosis and anticoagulants after a thrombotic event requires special attention and development of corresponding recommendations. The prescription of anticoagulants is impossible without taking into account the risks of hemorrhagic complications, which are also typical for myeloproliferative neoplasms.

Aim. Assessment of the impact of hereditary thrombophilia genetic markers on the risk of thrombotic complications in patients with PV.

Methods. The study examined 116 patients with PV, who were screened for markers of hereditary thrombophilia: factor V (G1691A, FV Leiden), prothrombin, methylenetetrahydrofolate reductase (MTHFR), fibrinogen (FI), plasminogen activator inhibitor (PAI-1), and platelet fibrinogen receptor type IIIA (GPIIIA). The incidence of these markers and their role in thrombosis in such patients was investigated.

Results. The study provided data on the incidence of hereditary thrombophilia markers in patients with PV. Statistically significant differences in the incidence of these markers and homocysteine level were found between patients with thrombosis and without them.

Conclusion. The information about the hereditary thrombophilia markers presence may be useful for the prescription of adequate antiaggregant and anticoagulant therapy for PV patients. Further research in this field is justified and it will probably demonstrate the relevance of hereditary thrombophilia markers as prognostic factors for thrombotic complications risk assessment.

Keywords: polycythemia vera, hereditary thrombophilia, thrombosis.

Received: December 11, 2016

Accepted: December 21, 2016

Read in PDF (RUS)pdficon

REFERENCES

  1. Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81(2):159–66. doi: 10.4065/81.2.159.
  2. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood. 2007;109(6):2310–3. doi: 10.1182/blood-2006-09-046342.
  3. Гусева С.А., Бессмельцев С.С., Абдулкадыров К.М., Гончаров Я.П. Истинная полицитемия. Киев, СПб.: Логос, 2009. 405 с.
    [Guseva SA, Bessmel’tsev SS, Abdulkadyrov KM, Goncharov YaP. Istinnaya politsitemiya. (Polycythemia vera.) Kiev, Saint Petersburg: Logos Publ.; 2009. 405 p. (In Russ)]
  4. Finazzi G, Rambaldi A, Guerini V, et al. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica. 2007;92(1):135–6. doi: 10.3324/haematol.10634.
  5. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2 V617F allele burden. Leukemia. 2007;21(9):1952–9. doi: 10.1038/sj.leu.2404854.
  6. Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999;13(2):150–4. doi: 10.1038/sj.leu.2401270.
  7. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755–61. doi: 10.1016/j.amjmed.2004.06.032.
  8. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33. doi: 10.1155/2011/794240.
  9. Hebbel RP, Boogaerts MA, Eaton JW, et al. Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Engl J Med. 1980;302(18):992–5. doi: 10.1056/nejm198005013021803.
  10. Wautier JL, Paton RC, Wautier MP, et al. Increased adhesion of erythrocytes to endothelial cells in diabetes mellitus and its relation to vascular complications. N Engl J Med. 1981;305(5):237–42. doi: 10.1056/nejm198107303050501.
  11. Wautier MP, El Nemer W, Gane P, et al. Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM. Blood. 2007;110(3):894–901. doi: 10.1182/blood-2006-10-048298.
  12. Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2012;2012(1):571–81.
  13. Goette NP, Lev PR, Heller PG, et al. Monocyte IL-2Ralpha expression is associated with thrombosis and the JAK2V617F mutation in myeloproliferative neoplasms. Cytokine. 2010;51(1):67–72. doi: 10.1016/j.cyto.2010.04.011.
  14. Jensen MK, De NullyBrown P, Lund BV, et al. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol. 2000;110(1):116–24. doi: 10.1046/j.1365-2141.2000.02030.x.
  15. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91(2):169–75.
  16. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. ACC Curr J Rev. 2004;13(4):4–10. doi: 10.1016/j.accreview.2004.03.074.
  17. Abdulkarim K, Ridell B, Johansson P, et al. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. Eur J Haematol. 2011;86(2):148–55. doi: 10.1111/j.1600-0609.2010.01548.x.
  18. Barbui T, Thiele J, Passamonti F, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood. 2012;119(10):2239–41. doi: 10.1182/blood-2011-11-393819.
  19. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179–84. doi: 10.1200/jco.2010.34.5298.
  20. Vaidya R, Gangat N, Jimma T, et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol. 2012;87(11):1003–5. doi: 10.1002/ajh.23295.
  21. Marchioli R., Finazzi G., Landolfi R, et al. Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera. J Clin Oncol. 2005;23(10):2224–32. doi: 10.1200/jco.2005.07.062.
  22. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123(9):656–64. doi: 10.7326/0003-4819-123-9-199511010-00003.
  23. Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117(22):5857–9. doi: 10.1182/blood-2011-02-339002.
  24. Stein BL, Saraf S, Sobol U, et al. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma. 2013;54(9):1989–95. doi: 10.3109/10428194.2012.759656.
  25. Giona F, Teofili L, Moleti ML, et al. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood. 2012;119(10):2219–27. doi: 10.1182/blood-2011-08-371328.
  26. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3):840–6. doi: 10.1182/blood-2006-12-064287.
  27. Alvarez-Larran A, Cervantes F, Bellosillo B, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21(6):1218–23. doi: 10.1038/sj.leu.2404693.
  28. Wolansky AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81(2):159–66. doi: 10.4065/81.2.159.
  29. Сervantes F, Alvarez-Larran A, Arellano-Rodrigo E, et al. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution. Leukemia. 2006;20(1):55–60. doi: 10.1038/sj.leu.2404048.
  30. Barbui T, Carobbio A, Cervantes F, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115(4):778–82. doi: 10.1182/blood-2009-08-238956.
  31. Gangat N, Wolanskyj AP, Tefferi A. Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications. Eur J Haematol. 2006;77(4):327–33. doi: 10.1111/j.1600-0609.2006.00715.x.
  32. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost. 2007;5(4):708–14. doi: 10.1111/j.1538-7836.2007.02424.x.
  33. Landolfi R, Di Gennaro L, Nicolazzi MA, et al. Polycythemia vera: gender-related phenotypic differences. Int Emerg Med. 2011;7(6):509–15. doi: 10.1007/s11739-011-0634-3.
  34. Grandone E, Colaizzo D, Tiscia GL, et al. Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation. Thromb Haemost. 2008;99(3):640–2. doi: 10.1160/th07-09-0570.
  35. Капустин С.И., Кармацкая И.И., Дрижун Ю.С. и др. Опыт диагностики наследственных факторов риска тромбоза у больных истинной полицитемией. Вестник гематологии. 2011;4:25–6.
    [Kapustin SI, Karmatskaya II, Drizhun YuS, et al. Experience in diagnosing of hereditary thrombosis risk factors in patients with polycythemia vera. Vestnik gematologii. 2011;4:25–6. (In Russ)]
  36. Капустин С.И., Шмелева В.М., Сидорова Ж.Ю. и др. Молекулярные детерминанты наследственной тромбофилии: современное состояние и перспективы генодиагностики (обзор литературы). Вестник гематологии. 2011;VII(4):84–90.
    [Kapustin SI, Shmeleva VM, Sidorova ZhYu, et al. Molecular determinants of hereditary thrombophilia: present state and perspectives of genetic diagnostics (literature review). Vestnik gematologii. 2011;VII(4):84–90. (In Russ)]
  37. Bick R., Kaplan H. Syndromes of thrombosis and hypercoagulability: congenital and acquired thrombophilias. Clin Appl Thromb Hemost. 1998;4(1):25–50. doi: 10.1177/107602969800400106.
  38. O’Shaughnessy D, Markis M, Lillicap D, eds. Practical hemostasis and thrombosis. Oxford: Blackwell Publishing; 2005. рр. 224. doi: 10.1002/9780470988633.
  39. Khan S, Dickerman JD. Hereditary thrombophilia. Thromb J. 2006;4(1):15. doi: 10.1186/1477-9560-4-15.
  40. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 2000;95(5):1517–32.
  41. Honda S, Honda Y, Baer B, et al. The impact of three-dimensional structure on the expression of P1A alloantigens on human integrin beta 3. Blood. 1995;86(1):234–42.
  42. Капустин С.И., Салтыкова Н.Б., Каргин В.Д. и др. Генетические факторы риска тромбоэмболии легочной артерии у больных с тромбозом глубоких вен. Клинико-лабораторный консилиум. 2007;16:56–60.
    [Kapustin SI, Saltykova NB, Kargin VD, et al. Genetic factors of risk of pulmonary embolism in patients with deep vein thrombosis. Kliniko-laboratornyi konsilium. 2007;16:56–60. (In Russ)]
  43. Undas A, Brozek J, Szczeklik A. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost. 2005;94(5):907–15. doi: 10.1160/th05-05-0313.
  44. Tevet M, Ionescub R, Dragan C, et al. Influence of the JAK2 V617F Mutation and Inherited Thrombophilia on the Thrombotic Risk among Patients with Myeloproliferative Disorders. J Clin Med. 2015;10(1):27–32.
  45. Gisslinger H, Mullner M, Pabinger I, et al. Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study. Haematologica. 2005;90(3):408–10.
  46. De Stefano V, Za T, Rossi E, et al. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica. 2009;94(5):733–7. doi: 10.3324/haematol.13869.
  47. Kreher S, Ochsenreither S,Trappe RU, et al. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (OGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). Ann Hematol. 2014;93(12):1953–63. doi: 10.1007/s00277-014-2224-8.
  48. Casini A, Fontana P, Lecompte TP. Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management. J Thromb Haemost. 2013;11(7):1215–27. doi: 10.1111/jth.12265.
  49. Stefano V, Za T, Rossi E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93(3):372–80. doi: 10.3324/haematol.12053.